Bris­tol My­ers scraps gene ther­a­py deal with uniQure for car­dio­vas­cu­lar dis­eases

Bris­tol My­ers Squibb is hit­ting the ex­it on a col­lab­o­ra­tion with a gene ther­a­py biotech.

The Big Phar­ma com­pa­ny will no longer part­ner with uniQure on find­ing new treat­ments for car­dio­vas­cu­lar dis­eases, the biotech re­port­ed to the SEC last week, fol­low­ing a rocky re­la­tion­ship that saw the pair break off an ear­li­er agree­ment — be­fore com­ing back to the ta­ble. The deal will of­fi­cial­ly ter­mi­nate on Feb. 21, 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.